About the Company

Erytech Pharma (NYSE Euronext: ERYP.PA) is a biopharmaceutical company developing unique, red blood cell-based treatments for cancer. The Company’s lead candidate is GRASPA/ERY-ASP, a red blood cell encapsulated L-asparaginase therapy designed to improve safety and minimize treatment duration. Positive data from a European Phase III trial of GRASPA in acute lymphoblastic leukemia (ALL) were reported in September 2014. Erytech plans to file for marketing approval in Europe in the second quarter of 2015. A US Phase II study is underway to expand into the US market.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research